Prenatal Treatment for Serious Neurological Sequelae of Congenital Toxoplasmosis: An Observational Prospective Cohort Study

English version České info

Background:
The effectiveness of prenatal treatment to prevent serious neurological sequelae (SNSD) of congenital toxoplasmosis is not known.

Methods and Findings:
Congenital toxoplasmosis was prospectively identified by universal prenatal or neonatal screening in 14 European centres and children were followed for a median of 4 years. We evaluated determinants of postnatal death or SNSD defined by one or more of functional neurological abnormalities, severe bilateral visual impairment, or pregnancy termination for confirmed congenital toxoplasmosis. Two-thirds of the cohort received prenatal treatment (189/293; 65%). 23/293 (8%) fetuses developed SNSD of which nine were pregnancy terminations. Prenatal treatment reduced the risk of SNSD. The odds ratio for prenatal treatment, adjusted for gestational age at maternal seroconversion, was 0.24 (95% Bayesian credible intervals 0.07–0.71). This effect was robust to most sensitivity analyses. The number of infected fetuses needed to be treated to prevent one case of SNSD was three (95% Bayesian credible intervals 2–15) after maternal seroconversion at 10 weeks, and 18 (9–75) at 30 weeks of gestation. Pyrimethamine-sulphonamide treatment did not reduce SNSD compared with spiramycin alone (adjusted odds ratio 0.78, 0.21–2.95). The proportion of live-born infants with intracranial lesions detected postnatally who developed SNSD was 31.0% (17.0%–38.1%).

Conclusion:
The finding that prenatal treatment reduced the risk of SNSD in infected fetuses should be interpreted with caution because of the low number of SNSD cases and uncertainty about the timing of maternal seroconversion. As these are observational data, policy decisions about screening require further evidence from a randomized trial of prenatal screening and from cost-effectiveness analyses that take into account the incidence and prevalence of maternal infection.

: Please see later in the article for the Editors' Summary

Vyšlo v časopise: Prenatal Treatment for Serious Neurological Sequelae of Congenital Toxoplasmosis: An Observational Prospective Cohort Study. PLoS Med 7(10): e32767. doi:10.1371/journal.pmed.1000351
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.pmed.1000351

Souhrn

Background:
The effectiveness of prenatal treatment to prevent serious neurological sequelae (SNSD) of congenital toxoplasmosis is not known.

Zdroje

1. RemingtonJS

McLeodR

ThulliezP

DesmontsG

2006 Toxoplasmosis.

RemingtonJS

KleinJ

WilsonCB

BakerCJ

Infectious disease of the fetus and newborn infant Philadelphia Elsevier Saunders 947 1092

2. Ferreira-da-SilvaMF

TakacsAC

BarbosaHS

GrossU

LuderCG

2009 Primary skeletal muscle cells trigger spontaneous Toxoplasma gondii tachyzoite-to-bradyzoite conversion at higher rates than fibroblasts. Int J Med Microbiol 299 381 388

3. ThiebautR

LeproustS

CheneG

GilbertRE

The SYROCOT Study Group 2007 Effectiveness of prenatal treatment for congenital toxoplasmosis: a meta-analysis of individual patients' data. Lancet 369 115 122

4. GilbertR

GrasL

2003 Effect of timing and type of treatment on the risk of mother to child transmission of Toxoplasma gondii. BJOG 110 112 120

5. FreemanK

TanHK

PrusaA

PetersenE

BuffolanoW

2008 Predictors of retinochoroiditis in children with congenital toxoplasmosis: European, prospective cohort study. Pediatrics 121 e1215 e1222

6. GrasL

WallonM

PollakA

Cortina-BorjaM

EvengardB

2005 Association between prenatal treatment and clinical manifestations of congenital toxoplasmosis in infancy: a cohort study in 13 European centers. Acta Paediatrica Scandinavia 94 1721 1731

7. LebechM

AndersenO

ChristensenNC

HertelJ

NielsenHE

1999 Feasibility of neonatal screening for toxoplasma infection in the absence of prenatal treatment. Lancet 353 1834 1837

8. PaulM

PetersenE

SzczapaJ

2001 Prevalence of congenital Toxoplasma gondii infection among newborns from the Poznan region of Poland: validation of a new combined enzyme immunoassay for Toxoplasma gondii-specific immunoglobulin A and immunoglobulin M antibodies. J Clin Microbiol 39 1912 1916

9. TanHK

SchmidtD

StanfordM

Tear-FahnehjelmK

FerretN

2007 Risk of visual impairment in children with congenital toxoplasmic retinochoroiditis. Am J Ophthalmol 144 648 653

10. BerrebiA

KobuchWE

BessieresMH

BloomMC

RollandM

1994 Termination of pregnancy for maternal toxoplasmosis. Lancet 344 36 39

11. Gay-AndrieuF

MartyP

PialatJ

SourniesG

DrierdL

2003 Fetal toxoplasmosis and negative amniocentesis: necessity of an ultrasound follow-up. Prenat Diagn 23 558 560

12. BerrebiA

BardouM

BessieresMH

NowakowskaD

CastagnoR

2007 Outcome for children infected with congenital toxoplasmosis in the first trimester and with normal ultrasound findings: a study of 36 cases. Eur J Obstet Gynecol Reprod Biol 135 53 57

13. GomezG

EspinalA

LagakosW

2003 Inference for a linear regression model with an interval-censored covariate. Stat Med 22 409 425

14. DunnD

WallonM

PeyronF

PetersenE

PeckhamCS

1999 Mother to child transmission of toxoplasmosis: risk estimates for clinical counselling. Lancet 353 1829 1833

15. GilbertRE

GrasL

WallonM

PeyronF

AdesAE

2001 Effect of prenatal treatment on mother to child transmission of Toxoplasma gondii: a cohort study of 554 mother-child pairs in Lyon, France. Int J Epidemiol 30 1303 1308

16. GrasL

GilbertRE

AdesAE

DunnDT

2001 Effect of prenatal treatment on the risk of intracranial and ocular lesions in children with congenital toxoplasmosis. Int J Epidemiol 30 1309 1330

17. WallonM

DunnD

SlimaniD

GiraultV

Gay-AndrieuF

1999 Diagnosis of congenital toxoplasmosis at birth: what is the value of testing for IgM and IgA? Eur J Pediatr 158 645 649

18. GilbertRE

ThalibL

TanHK

PaulM

WallonM

2007 Screening for congenital toxoplasmosis: accuracy of immunoglobulin M and immunoglobulin A tests after birth. J Med Screen 14 8 13

19. HeinemanKR

Hadders-AlgraM

2008 Evaluation of neuromotor function in infancy-A systematic review of available methods. J Dev Behav Pediatr 29 315 323

20. BrooksS

GelmanA

1998 General methods for monitoring convergence of iterative simulations. J Comput Graph Stat 7 434 455

21. SpiegelhalterD

BestN

CarlinB

van der LindeA

2002 Bayesian measures of complexity and fit. J R Stat Soc Series B Stat Methodol 583 639

22. PaulM

PetersenE

PawlowskiZS

SzczapaJ

2000 Neonatal screening for congenital toxoplasmosis in the Poznan region of Poland by analysis of Toxoplasma gondii-specific IgM antibodies eluted from filter paper blood spots. Pediatr Infect Dis J 19 30 36

23. EvengardB

PettersonK

EngmanM-L

WiklundS

IvarssonSA

2001 Low incidence of toxoplasma infection during pregnancy and in newborns in Sweden. Epidemiol Infect 127 121 127

24. DaveluyA

HaramburuF

BricoutH

CostanzoMC

FourrierA

2005 Review of data related to side effects of drugs used in congenital toxoplasmosis. Panel 2. [Unpublished report]. Bordeaux (France): The Eurotoxo Group. Available at http://eurotoxo.isped.u-bordeaux2.fr/WWW_PUBLIC/DOC/Side_effects_main_drugs_v3.pdf. Accessed 10 September 2010

25. FoulonW

VillenaI

Stray-PedersenB

DecosterA

LappalainenM

1999 Treatment of toxoplasmosis during pregnancy: a multicentre study of impact on fetal transmission and children's sequelae at age 1 year. Am J Obstet Gynecol 180 410 415

26. GilbertRE

PeckhamCS

2002 Congenital toxoplasmosis in the United Kingdom: to screen or not to screen? J Med Screen 9 135 141

27. HernanMA

Hernandez-DiazS

WerlerMM

MitchellAA

2002 Causal knowledge as a prerequisite for confounding evaluation: an application to birth defects epidemiology. Am J Epidemiol 155 176 184

28. FreemanK

OakleyL

PollakA

BuffolanoW

PetersenE

2004 Congenital toxoplasmosis and preterm birth, low birth weight, and small for gestational age birth. BJOG 112 31 37

29. GrasL

GilbertRE

WallonM

PeyronF

Cortina-BorjaM

2004 Duration of the IgM response in women acquiring Toxoplasma gondii during pregnancy: implications for clinical practice and cross-sectional incidence studies. Epidemiol Infect 132 541 548

30. LevineD

FeldmanHA

TannusJF

EstroffJA

MagninoM

2008 Frequency and cause of disagreements in diagnoses for fetuses referred for ventriculomegaly. Radiology 247 516 527

31. GilbertRE

FreemanK

LagoEG

Bahia-OliveiraLM

TanHK

2008 Ocular sequelae of congenital toxoplasmosis in Brazil compared with Europe. PLoS Negl Trop Dis 2 e277 doi:10.1371/journal.pntd.0000277